




MEDICINAL PRODUCTS 2023

MYRIAD GENETICS INC
Rank 17 of 48





MEDICINAL PRODUCTS 2023

MYRIAD GENETICS INC Rank 17 of 48



The relative strengths and weaknesses of MYRIAD GENETICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MYRIAD GENETICS INC compared to the market average is the variable Goodwill, increasing the Economic Capital Ratio by 36% points. The greatest weakness of MYRIAD GENETICS INC is the variable Assets, Current, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 85%, being 90% points above the market average of -5.0%.

Input Variable	Value in 1000 USD
Assets, Current	274,600
Assets, Non-Current	174,200
General and Administrative Expense	514,700
Goodwill	666,500
Liabilities, Current	140,700
Liabilities, Non-Current	145,400
Other Assets	0
Other Compr. Net Income	-3,800
Other Expenses	190,300
Other Liabilities	26,800
Other Net Income	0
Other Revenues	678,400
Property, Plant and Equipment, Net	83,400
Research and Development	85,400

Output Variable	Value in 1000 USD
Liabilities	312,900
Assets	1,198,700
Expenses	790,400
Revenues	678,400
Stockholders Equity	885,800
Net Income	-112,000
Comprehensive Net Income	-113,900
Economic Capital Ratio	85%